GA
GYRE icon

GoalVest Advisory’s Gyre Therapeutics GYRE Stock Holding History

GoalVest Advisory’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330 Hold
50
– – ﹤0.01% 494
2026
Q1 		$349 Buy
+50
New +$388 ﹤0.01% 439

Other funds holding GYRE

AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GoalVest Advisory's GYRE Position: Q2 2026 in Review

GoalVest Advisory held its Gyre Therapeutics (GYRE) position steady in Q2 2026 at 50 shares worth $330. The position accounts for ﹤0.01% of the portfolio, ranked #494.

GoalVest Advisory first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $349 in Q1 2026. 4 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • GoalVest Advisory held 50 shares of Gyre Therapeutics worth $330 as of Q2 2026.
  • GoalVest Advisory left its Gyre Therapeutics share count unchanged in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of GoalVest Advisory's portfolio in Q2 2026, its #494 holding.
  • GoalVest Advisory first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GoalVest Advisory's Gyre Therapeutics position peaked at $349 in Q1 2026.
  • 4 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.